Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder.
An intriguing new study has suggested that there could be a correlation between the built environment of an area – its buildings, streets, and green spaces – and the risk
Artificial intelligence-powered software developed by Brainomix has been shown to identify patients with idiopathic pulmonary fibrosis (IPF) at risk of decline in a clinic
Teva’s UK subsidiary has joined forces with techbio company Closed Loop Medicine to use its software as a medical device (SaMD) technology platform in the development of n
Just four months after ending an 18-year stint as chief executive of BioMarin, Jean-Jacques Bienaimé, has been named chairman of Owkin, a specialist in applying artificial
Three digital health technologies (DHTs) used to support patients with psychosis can be used by the NHS while additional evidence of their benefits is gathered.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.